Dapagliflozin reduces systemic PCSK9 levels in preclinical models of short-term doxorubicin cardiotoxicity through NLRP3 inflammasome/IL-1β: a first evidence of SGLT-2/PCSK9 cross-talk in cardioncology
Anno:
2023
Background: Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the development of cardiac dysfunction, arrhythmias, and clinical heart failure. In recent five…